Recommended Topic Related To:

Oncaspar

"The U.S. Food and Drug Administration today approved Zarxio (filgrastim-sndz), the first biosimilar product approved in the United States.

Biological products are generally derived from a living organism. They can come from many sources, in"...

Oncaspar




Overdosage
Contraindications

OVERDOSE

Three patients received 10,000 International Units/m² of Oncaspar® as an intravenous infusion. One patient experienced a slight increase in liver enzymes. A second patient developed a rash 10 minutes after the start of the infusion, which was controlled with the administration of an antihistamine and by slowing down the infusion rate. A third patient did not experience any adverse reactions.

CONTRAINDICATIONS

  • History of serious allergic reactions to Oncaspar® .
  • History of serious thrombosis with prior L-asparaginase therapy.
  • History of pancreatitis with prior L-asparaginase therapy.
  • History of serious hemorrhagic events with prior L-asparaginase therapy.

Last reviewed on RxList: 5/2/2014
This monograph has been modified to include the generic and brand name in many instances.

Overdosage
Contraindications
A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Cancer

Get the latest treatment options.